Month: February 2026

SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, Feb. 12, 2026 (GLOBE NEWSWIRE) — Adlai Nortye Ltd. (NASDAQ: ANL) (the “Company” or “Adlai Nortye”), a clinical-stage biotechnology company focused on the development of innovative cancer therapies, today announced that the first patient has been dosed in the United States in early February in its ongoing Phase 1 clinical trial of AN9025, a pan-RAS (ON) inhibitor. The Phase 1 study is a first-in-human, multicenter, open-label trial designed to evaluate the safety, tolerability, pharmacokinetics and anti-tumor activity of AN9025 in patients with advanced or metastatic solid tumors harboring RAS mutations. This trial is being conducted by Adlai Nortye in collaboration with Jiangsu Aosaikang Pharmaceutical Co. Ltd. (“ASK Pharm”) as a multi-regional clinical trial (“MRCT”) pursuant...

WILMINGTON, Del., Feb. 12, 2026 (GLOBE NEWSWIRE) — InterDigital, Inc. (Nasdaq: IDCC), a global wireless, video, and AI research and development company, announced that Atle Monrad has been re-elected for a second term to Chair the 3GPP SA6 working group. SA6 is responsible for service architecture, procedures, and information flows that enable applications, vertical services, and critical communications. The group’s work ensures network capabilities can be effectively exposed and leveraged by vertical industries, emerging service providers, and public safety organizations. Following a first term focused on strengthening service exposure and application enablement for 5G and 5G-Advanced, Atle’s second term will place increased emphasis on defining service frameworks and requirements to support the development of next-generation...

Tokyo, Japan and Cambridge, UK, 12 February 2026 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) today notes that Centessa Pharmaceuticals has achieved an early development milestone associated with its investigational, orally administered, highly potent and selective orexin receptor 2 (OX2R) agonist, ORX489, being developed by Centessa for the treatment of neuropsychiatric disorders. This milestone triggers a payment of US$1.8 million to Nxera pursuant to its research collaboration with Centessa. The milestone payment will be recognized as revenue in the first quarter of 2026.   –END– About Nxera PharmaNxera Pharma is a technology powered biopharma company in pursuit of new specialty medicines to improve the lives of patients with unmet needs in Japan and globally. The Company has built an agile, new-generation commercial...

New company established by a leading international life sciences investment firmTokyo, Japan and Cambridge, UK, 12 January 2026 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) announced that it has entered into a license agreement (the “Agreement”) with a newly established independent company (the “NewCo”), created by a leading international life sciences investment firm, to advance Nxera’s G protein-coupled receptor (GPCR)-targeted program (the “Program”). Under the Agreement, Nxera has received an equity stake in NewCo and upon successful development and commercialization of the asset, Nxera is entitled to receive milestone payments and royalties from sales. Under the terms of the agreement, Nxera has retained certain rights to develop and commercialize the asset in Japan and certain Asia-Pacific territories in the...

Pursuant to section 30 of the Danish Capital Markets Act, Solar A/S hereby announces that UBS Group AG has informed Solar that following its purchase of shares on 9 February 2026, UBS Group AG holding of Solar B shares now totals 407,439 shares at DKK 100, corresponding to an ownership share of 5.09%. ContactsCEO Jens Andersen – tel. +45 79 30 02 01CFO Michael H. Jeppesen – tel. +45 79 30 02 62IR Director Dennis Callesen – tel. +45 29 92 18 11 Facts about Solar Solar is a leading European sourcing and services company mainly within electrical, heating and plumbing, ventilation and climate and energy solutions. Our core business centres on product sourcing, value-adding services and optimisation of our customers’ businesses. We facilitate efficiency improvement and provide digital tools that turn our customers into winners....

On 11 February 2026, Hepsor E18 SIA and BluOr Bank AS signed a loan agreement in the amount of 5.25 million euros. The five-year loan is intended to finance the construction and infrastructure development of the Ķiršu Kalna Mājas residential project at Eiženijas iela 18, Dzirciems, Riga. The development includes the construction of two apartment buildings with a total of 54 apartments. Construction and sales of the project have already commenced, and the planned completion date is the first quarter of 2027. The total cost of the development project is 8.5 million euros. At the time of signing the loan agreement, 41% of the apartments in the project had been reserved or pre-sold. More information about the “Ķiršu Kalna Mājas” project is available at:https://hepsor.lv/kirsukalnamajas/ To date, Hepsor has completed a total of 404 homes in...

Zug, 12 February 2026 – Multitude AG, a listed European FinTech company, offering digital lending and online banking services to consumers, small and medium-sized enterprises, and other FinTechs (WKN: A40VJN, ISIN: CH1398992755) (“Multitude”, “Company” or “Group”) warmly invites financial analysts, investors, and media to its FY2025 Preliminary Results Presentation webcast.  The event will be held virtually on Thursday, 12 March 2026, at 10:00 am CET.   A link for registration to the webcast is available on the company website in the subsection financial calendar https://www.multitude.com/investors/financial-calendar.  Contact:  Multitude AG  Grafenauweg 8   6300 Zug  Switzerland   Adam Hansson Tönning Head of IR and Treasury Phone: +46733583171ir@multitude.com  About Multitude AG:   Multitude is a listed European FinTech company, offering...

Stockholm, February 12, 2026 – Virtune, a Swedish regulated crypto asset manager, today announces the listing of Virtune BNB ETP on Deutsche Börse Xetra, one of Europe’s leading regulated trading venues. About Virtune BNB ETP Virtune BNB ETP is a physically backed exchange-traded product designed to offer investors a secure and cost-effective way to gain exposure to BNB. This is achieved through a transparent, physically backed structure with institutional-grade security. Virtune BNB ETP:1:1 exposure to BNB 100% physically backed by the underlying asset BNB held in cold-storage with Coinbase 1.95% annual management fee First day of trading: Thursday, February 12, 2026 Xetra Exchange Ticker: VBNB Trading currency: EUR ISIN: SE0027598202 WKN: A4ARBWAbout BNB BNB is the native crypto asset of the BNB Chain ecosystem and is used across...

Vancouver, British Columbia, Feb. 12, 2026 (GLOBE NEWSWIRE) — NEW EARTH RESOURCES CORP. (CSE: EATH) (“New Earth” or the “Company”) is pleased to announce that it has submitted an application to the Arizona State Land Department for approximately 268 acres of additional state mineral lease land contiguous to its past-producing Lucky Boy Uranium Project. If approved, the additional acreage would nearly double the Company’s current land position within the Lucky Boy area. The applied-for acreage is located directly adjacent to the Company’s existing project area and represents a strategic expansion of New Earth’s land position within the broader Lucky Boy area. The Company believes that securing additional state lease ground will strengthen its overall property position and support long-term planning for the project. The additional...

Premier User Test Conference to Feature 10 Technical Tracks, Partner’s Expo, Keynotes, Workshop Day and More TOKYO, Feb. 12, 2026 (GLOBE NEWSWIRE) — Leading semiconductor test equipment supplier Advantest Corporation (TSE: 6857) has opened registration for its VOICE 2026 Developer Conference, held on May 18-20, at the Fairmont Scottsdale Princess in Scottsdale, Arizona. This year’s conference is open to the international community of users and strategic partners engaged with Advantest’s SoC test platforms, namely V93000 and T2000. The event will feature more than 80 technical presentations organized into 10 tracks, including a new Silicon Photonics track. A Technology Kiosk Showcase will highlight a wide array of Advantest’s test solutions, including system-level test, material handling test cells, device interfaces...